1. Home
  2. OPTH vs BYSI Comparison

OPTH vs BYSI Comparison

Compare OPTH & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Optimi Health Corp. Common Shares

OPTH

Optimi Health Corp. Common Shares

N/A

Current Price

$4.63

Market Cap

28.9M

Sector

N/A

ML Signal

N/A

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

N/A

Current Price

$0.78

Market Cap

31.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPTH
BYSI
Founded
2020
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.9M
31.4M
IPO Year
2024
2016

Fundamental Metrics

Financial Performance
Metric
OPTH
BYSI
Price
$4.63
$0.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
65.9K
★ 306.2K
Earning Date
08-14-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$56.17
N/A
Revenue Next Year
$82.70
$49.96
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.00
$0.57
52 Week High
$5.45
$2.44

Technical Indicators

Market Signals
Indicator
OPTH
BYSI
Relative Strength Index (RSI) 47.10 48.52
Support Level $4.17 $0.61
Resistance Level $5.15 $0.80
Average True Range (ATR) 0.27 0.09
MACD -0.02 0.02
Stochastic Oscillator 45.24 32.65

Price Performance

Historical Comparison
OPTH
BYSI

About OPTH Optimi Health Corp. Common Shares

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: